Literature DB >> 3023487

The released interleukin 2 receptor binds interleukin 2 efficiently.

L A Rubin, G Jay, D L Nelson.   

Abstract

The released interleukin 2 receptor (IL 2R) molecule was characterized in order to clarify its biochemical structure and to determine its functional capacity. Enzymatic digestions demonstrated that the released IL 2R, like the cell surface IL 2R, is a complex glycoprotein, modified by the addition of both N- and O-linked carbohydrates and sialic acid residues. It has a peptide backbone that is approximately 10 Kd smaller than that of its membrane-associated counterpart. Affinity chromatography demonstrated that released IL 2R from either an HTLV-I-positive T cell line (HUT-102) or PHA-activated normal peripheral lymphocytes binds efficiently to purified recombinant IL 2. Furthermore, the interaction between the growth factor and the released receptor does not appear to require any accessory molecules. These observations suggest a potentially significant role for the released IL 2R in the regulation of IL 2-dependent lymphocyte functions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3023487

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Evaluation of serum levels of tumour necrosis factor-alpha (TNF-alpha) and soluble IL-2 receptor (sIL-2R) and CD4, CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment.

Authors:  L A Santana-Blank; M Castes; M E Rojas; F Vargas; D Scott-Algara
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

2.  Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias.

Authors:  S H Lim; C Worman; A Jewell; C Tsakona; F J Giles; A Goldstone
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus.

Authors:  P Airŏ; S Braga; E Prati; D Brugnoni; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

4.  Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy.

Authors:  J I Duncan; C Horrocks; A D Ormerod; A V Powles; P H Whiting; L Fry; A W Thomson
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

5.  Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus.

Authors:  J Hayashi; Y Kishihara; K Yamaji; E Yoshimura; M Ohmiya; Y Tani; H Ikematsu; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

6.  Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course.

Authors:  A J Swaak; R Q Hintzen; V Huysen; H G van den Brink; J T Smeenk
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

7.  Cytokines predict coronary aneurysm formation in Kawasaki disease patients.

Authors:  C Y Lin; C C Lin; B Hwang; B N Chiang
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

8.  Increased in vitro release of soluble interleukin 2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease.

Authors:  S Schreiber; A Raedler; A R Conn; J L Rombeau; R P MacDermott
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

Review 9.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

10.  Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy.

Authors:  C Soubrane; R Mouawad; M Ichen; J Suissa; C Borel; E Vuillemin; A Benhammouda; J P Bizzari; M Weil; D Khayat
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.